NUVALENT INC's ticker is and the CUSIP is 670703107. A total of 159 filers reported holding NUVALENT INC in Q4 2023. The put-call ratio across all filers is 0.25 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,075 | -12.1% | 27,353 | -13.0% | 0.00% | 0.0% |
| Q1 2024 | $2,361 | -63.6% | 31,450 | -64.3% | 0.00% | -50.0% |
| Q4 2023 | $6,484 | +175.3% | 88,105 | +71.9% | 0.00% | +100.0% |
| Q3 2023 | $2,355 | +29.2% | 51,243 | +18.5% | 0.00% | 0.0% |
| Q2 2023 | $1,823 | +121.8% | 43,233 | +37.1% | 0.00% | – |
| Q1 2023 | $822 | -6.3% | 31,523 | +7.1% | 0.00% | – |
| Q4 2022 | $877 | -93.7% | 29,438 | +4005.7% | 0.00% | – |
| Q3 2022 | $14,000 | +27.3% | 717 | -15.4% | 0.00% | – |
| Q2 2022 | $11,000 | -73.2% | 848 | -71.5% | 0.00% | – |
| Q1 2022 | $41,000 | – | 2,976 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 19,991,024 | $843,021,482 | 18.00% |
| Fairmount Funds Management LLC | 2,884,492 | $121,639,028 | 17.15% |
| Bain Capital Life Sciences Investors, LLC | 3,577,267 | $150,853,349 | 15.54% |
| COMMODORE CAPITAL LP | 1,150,000 | $48,495,500 | 5.45% |
| Paradigm Biocapital Advisors LP | 1,120,465 | $47,250,009 | 3.65% |
| Perceptive Advisors | 2,194,821 | $92,555,602 | 2.68% |
| Boxer Capital, LLC | 1,210,192 | $51,034 | 2.37% |
| Ikarian Capital, LLC | 272,752 | $11,501,952 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 115,067 | $4,852,375 | 1.50% |
| HighVista Strategies LLC | 72,298 | $3,048,807 | 1.40% |